S. Toyoizumi

发表

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study

Y. Shibasaki, M. Ohtsuki, S. Imafuku, 2016, The Journal of dermatology.

Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

Yoshiya Tanaka, S. Toyoizumi, Makoto Suzuki, 2011, Arthritis care & research.

Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data

H. Yamanaka, Yoshiya Tanaka, T. Takeuchi, 2019, Modern rheumatology.

Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open

T. Hibi, B. Ye, T. Hisamatsu, 2022, Journal of gastroenterology and hepatology.

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

H. Iwata, K. Yonemori, N. Masuda, 2022, Breast Cancer.

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

M. Ikeda, N. Matsubara, Y. Naito, 2021, Investigational New Drugs.

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

H. Yamanaka, Yoshiya Tanaka, T. Takeuchi, 2016, Arthritis Research & Therapy.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

H. Yamanaka, Yoshiya Tanaka, T. Takeuchi, 2015, Modern rheumatology.

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers

S. Miyoshi, S. Krishnaswami, S. Toyoizumi, 2019, Clinical pharmacology in drug development.

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

Yoshiya Tanaka, H. Valdez, T. Stock, 2018, Rheumatology.

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

K. Imaizumi, M. Nishio, H. Kenmotsu, 2023, JTO clinical and research reports.

THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

T. Hendrikx, R. V. van Vollenhoven, M. Collinge, 2015 .

Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

Yoshiya Tanaka, S. Toyoizumi, Makoto Suzuki, 2011, Arthritis care & research.